Ironwood Pharmaceuticals' 2025 Q4 Call: Strategic Shifts, Enrollment Timelines, and LINZESS Pricing Signals Clash

Date of Call: Feb 25, 2026

Financials Results

• Revenue: $296 million total revenue for full year 2025
• EPS: GAAP net income $24 million for full year 2025

Guidance:

• LINZESS U.S. net sales between $1.125B and $1.175B in 2026, a >30% increase YOY driven by improved net price and low single-digit prescription demand growth.
• Ironwood revenue between $450M and $475M in 2026.
• Adjusted EBITDA of >$300M in 2026.

Business Commentary:

LINZESS Performance and Market Leadership:

• Ironwood Pharmaceuticals reported LINZESS U.S. net sales of $865 million for the full year 2025, with an 11% year-over-year demand growth and 8% new-to-brand volume growth.
• The growth was supported by the FDA approval for the treatment of irritable bowel syndrome with constipation in patients 7 years of age and older, and the brand maintained its prescription market leadership with roughly 45% market share.

Financial Position and Outlook:

• The company delivered $138 million in adjusted EBITDA for 2025 and ended the year with $250 million in cash and cash equivalents.
• Improved financial position is attributed to disciplined expense management, including a $61 million reduction in operating expenses year-over-year, and strong cash flows from operations.

Apraglutide Development and Trial Design:

• The company is advancing apraglutide with the initiation of the STARS-2 Phase III clinical trial, expected to begin site activation in the second quarter of 2026.
• The design of the trial incorporates learnings from the prior STARS Phase III trial to optimize dose administration and ensure accurate dosing, aiming for an eventual NDA submission.

2026 Financial Guidance and LINZESS Pricing Strategy:

• For 2026, Ironwood expects LINZESS U.S. net sales to increase by more than 30% year-over-year, projected to be between $1.125 billion and $1.175 billion.
• The anticipated sales growth is driven by the elimination of the inflationary component of statutory required rebates due to a lower LINZESS list price, alongside low single-digit prescription demand growth.

Sentiment Analysis:

Overall Tone: Positive

• "We ended 2025 in a strong financial position, achieving our latest full year 2025 guidance." "We are entering 2026 in a position of renewed financial strength..." "Our conviction for the commercial opportunity for apraglutide remains high..." "We are particularly excited about the opportunity we have with apraglutide..."

Q&A:

• Question from Jason Butler (Citizens): Can you give any more details on the learnings from STARS and the refined options for use that you're now including in STARS-2? What gives you the confidence in repeating the data from STARS 1? And how should we think about the ability to enroll the trial on the timeline you gave and the similarities of the patient populations?
  Response: The main difference in STARS-2 is improved instructions for use and dose administration to ensure accuracy. Confidence in repeating the primary endpoint comes from the successful STARS trial and the refined execution plan. Enrollment is expected to be successful and on time, leveraging lessons from STARS and existing sites.

• Question from Chase Knickerbocker (Craig-Hallum): How are you thinking about the strategic alternatives process now that you can clearly continue as a stand-alone company or retire debt?
  Response: The company is in a different financial position now and will focus on executing its plan to leverage LINZESS revenue and reduce debt, while remaining open to alternatives that increase shareholder value.

• Question from Chase Knickerbocker (Craig-Hallum): STARS-2 enrollment timeline seems similar to STARS 1. What assumptions are you making on the total enrollment and how does it compare?
  Response: The assumptions are based on the successful execution of the original STARS trial. The team believes it can achieve the enrollment targets for STARS-2 and deliver the trial as projected.

• Question from Chase Knickerbocker (Craig-Hallum): As we approach the negotiated price for LINZESS, what have you seen in the market from prior negotiated drugs regarding volume acceleration, and how should we think about 2027?
  Response: The company is optimistic about LINZESS's future but has not provided specific guidance for 2027 and beyond.

• Question from Amy Li (Jefferies): How much of your existing clinical data is the FDA allowing you to reference for a future NDA? Was the trial size of 124 patients by FDA request or your conservative decision? Could you add a higher dose arm to maximize efficacy differentiation?
  Response: The FDA is expected to allow the use of original STARS data in the NDA submission, bridging on the aligned dose. The sample size of 124 patients was chosen for robust power. A higher dose is being considered but the current focus is on fastest path to market with the 3.5mg dose.

• Question from Mohit Bansal (Wells Fargo): Did you see data from the STARS trial to look at patients who could achieve the optimum dose? What is the latest on GATTEX generic and how are you thinking about the market opportunity for apra?
  Response: The STARS trial showed robust efficacy with a well-tolerated 3.5mg dose, which is being taken forward. Conviction in apraglutide's commercial potential remains high, expecting >$700M in U.S. peak net sales even with potential generics, as the market may not be multisourced.

• Question from Dominic Rose (Intron Health): What drove the LINZESS rebate in Q4 and should we expect ongoing pricing volatility? Also, what is the formulary positioning this year versus prior year given the volume fall at the start of the year?
  Response: The Q4 pricing impact was due to timing of gross-to-net rebate recognition, not channel mix. 2026 pricing is expected to be more consistent quarter-over-quarter. Formulary positioning remains strong with maintained broad patient access, and the initial volume reduction is attributed to normal seasonal seasonality.

Contradiction Point 1

Strategic Alternatives and Financial Outlook

Shift from exploring strategic alternatives to focusing solely on execution.

Chase Knickerbocker (Craig-Hallum) - Chase Knickerbocker (Craig-Hallum)

20260225-2025 Q4: The company is in a much stronger financial position and has a clear path forward, leveraging LINZESS revenue and reducing debt. They remain open to alternatives that increase shareholder value but will focus on executing their strategy. - Thomas McCourt(CEO) and Greg Martini(CFO)

Can you update us on strategic alternatives given a stronger financial position, discuss STARS-2 enrollment timeline assumptions compared to STARS 1, and provide the outlook for LINZESS in 2027 as the negotiated price approaches? - Matt Cowper (Leerink Partners, on for Faisal Khurshid)

2024Q4: The focus for 2025 is on strengthening the balance sheet by driving profits and cash flows to repay existing debt. Further details on balance sheet decisions will be provided as plans are made. - Greg Martini(CFO)

Contradiction Point 2

Enrollment Timeline Assumptions

Confidence in enrollment timeline shifts from being based on past performance to being based on trial attractiveness.

What are your revenue growth expectations for the upcoming quarter? - Chase Knickerbocker (Craig-Hallum)

20260225-2025 Q4: Enrollment assumptions are based on the successful execution of STARS 1. The trial is attractive to patients due to the drug's high probability of success, strong efficacy, excellent tolerability, and a 24-week duration. - Thomas McCourt(CEO) and Greg Martini(CFO)

Could you update us on your thinking regarding strategic alternatives given your stronger financial position, discuss assumptions for the STARS-2 enrollment timeline compared to STARS 1, and provide the outlook for LINZESS in 2027 as negotiated prices approach? - Chase Knickerbocker (Craig-Hallum)

2024Q4: For R&D, 2025 expenses are not expected to decline year-over-year due to ongoing activities for the apraglutide extension study and commercial launch preparations. A potential inflection in R&D spend is anticipated in 2026. - Greg Martini(CFO)

Contradiction Point 3

LINZESS Pricing Outlook

Change from expecting a headwind and providing no 2027 guidance to being optimistic about strong net sales.

Chase Knickerbocker (Craig-Hallum) - Chase Knickerbocker (Craig-Hallum)

20260225-2025 Q4: The company is optimistic about LINZESS's future and its ability to drive strong net sales. - Thomas McCourt(CEO), Greg Martini(CFO)

What is the 2027 outlook for LINZESS with the negotiated price? - Amy Li (Jefferies)

2024Q3: A pricing headwind is expected in 2025, but specific guidance will be provided later in the year. - Sravan Emany(CFO)

Contradiction Point 4

Strategic Focus on Alternatives

Shift from actively pursuing to being open but focused on execution.

Chase Knickerbocker (Craig-Hallum) - Chase Knickerbocker (Craig-Hallum)

20260225-2025 Q4: The company is in a much stronger financial position and has a clear path forward... They remain open to alternatives that increase shareholder value but will focus on executing their strategy. - Thomas McCourt(CEO), Greg Martini(CFO)

How are strategic alternatives being reconsidered given a stronger financial position? - David Amsellem (Piper Sandler)

2024Q3: The objective is to increase profitability. The company is critically evaluating all investments, including contracting strategies to maximize the bottom line. - Thomas McCourt(CEO)

Contradiction Point 5

LINZESS Rebate Volatility and Financial Forecasting

Contradiction on the predictability of LINZESS pricing and rebate recognition.

Dominic Rose (Intron Health) - Dominic Rose (Intron Health)

20260225-2025 Q4: The Q4 impact was due to the timing of recognizing gross-to-net rebates... This was not due to channel mix. Full-year 2025 results were more normalized. The company does not expect the same degree of quarterly volatility in 2026, anticipating more consistent pricing sequentially. - Greg Martini(CFO) and Tammi Gaskins(CCO)

What factors caused LINZESS rebate volatility in Q4, and will pricing volatility persist? - Timothy Chiang (Capital One)

2024Q2: The $17M adjustment in Q2 was specific to reflecting the updated LINZESS gross-to-net reserve. The guidance for 2024 already accounts for increased Medicaid utilization, and future quarterly adjustments were not discussed. - Sravan Emany(CFO)